The Personalized Medicine Coalition said last week that it has appointed Dietrich Stephan and Clay Marsh to serve on its board of directors.
Stephan is founder and chief science officer of Navigenics. He is also founder and CEO of the recently created Ignite Institute, and he also founded Amnestix and Aeuon. He previously served as a senior investigator in neurogenomics and deputy director of discovery research at the Translational Genomics Research Institute.
Marsh is director of the Center for Critical Care and executive director of the Center for Personalized Medicine at the Ohio State University Medical Center.
Osmetech Molecular Diagnostics has named John Bellano to be senior vice president of commercial operations. Bellano recently was VP of sales at Third Wave Technologies, a position he continued to hold after Third Wave was acquired by Hologic in 2008.